NCT05928182

Brief Summary

Study team members from El Futuro in Durham, North Carolina have created an intervention called El Faro. El Faro helps Latinx families of children with ADHD understand and cope with the stress and difficulties presented by the disorder. We propose to develop a community-engaged research partnership between El Futuro and the Duke ADHD Program that aims to pilot-test an adapted El Faro treatment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
32

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 23, 2023

Completed
10 days until next milestone

First Posted

Study publicly available on registry

July 3, 2023

Completed
3 months until next milestone

Study Start

First participant enrolled

October 10, 2023

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2024

Completed
Last Updated

July 30, 2024

Status Verified

November 1, 2023

Enrollment Period

8 months

First QC Date

June 23, 2023

Last Update Submit

July 29, 2024

Conditions

Keywords

Psychiatric HealthChildrenADHDLatinx Community

Outcome Measures

Primary Outcomes (9)

  • Preliminary Treatment Efficacy of adapted EL Faro as measured by change in the ADHD Rating Scale (ADHD-RS)

    An 18-item questionnaire with a 4-point Likert scale ranging from Never or Rarely (0) - Very Often (3). With a total score range of 0 -54. A lower score indicated a better outcome.

    (8 weeks)

  • Preliminary Treatment Efficacy of adapted EL Faro as measured by change in the ADHD Functional Impairment Scale (ADHD-FX)

    A 32-item questionnaire with 4-point Likert scale ranging from Not at All (0) - A lot (3). With a total score range of 0 - 96. A lower score indicates better outcome.

    (8 weeks)

  • Preliminary Treatment Efficacy of adapted EL Faro as measured by change in the Attention Problem Scale of the Child Behavior Checklist (CBCL)

    A 10-item parent report questionnaire with a 3-point Likert Scale ranging from Not True (0) to Very True or Often True (2). A total score range of 0-20. Lower scores indicate better outcomes.

    (8 weeks)

  • Preliminary Treatment Efficacy of adapted EL Faro as measured by change in the ADHD Scale of the Child Behavior Checklist (CBCL)

    A 7-item parent report questionnaire with a 3-point Likert Scale ranging from Not True (0) to Very True or Often True (2). A total score range of 0-14. Lower scores indicate a better outcome.

    (8 weeks)

  • Preliminary Treatment Efficacy of adapted EL Faro as measured by change in the Parenting Sense of Competence Scale (PSOC)

    A 16-item questionnaire with a 6-point Likert scale ranging from Strongly Disagree (1) - Strongly Agree (6). A total score range of 16 - 96. A higher score indicates a better outcome.

    (8 weeks)

  • Feasibility of adapted El Faro Treatment as measured by percentage of attrition

    Attrition of \<25% will be set to establish feasibility

    (8 weeks)

  • Feasibility of adapted El Faro Treatment as measured by homework compliance

    8 weeks

  • Acceptability of adapted El Faro Treatment as measured by how satisfactory participants felt that the treatment was overall

    Acceptability will be based on how satisfactory participants felt that the treatment was overall (ranging from 1-7 with 7 indicating the highest rating of treatment satisfaction)

    8 weeks

  • Acceptability of adapted El Faro Treatment as measured by caregiver perceptions

    Caregiver perceptions about the extent of ADHD psychoeducation they received, how the content was relevant to their experiences, whether the techniques introduced were understandable, if they were confident about regularly using the techniques taught, and if they would recommend El Faro to other families of children with ADHD (on a scale ranging from 1 = not at all to 4 = extremely).

    8 weeks

Study Arms (1)

Treatment Participants

EXPERIMENTAL

Active treatment group participants

Behavioral: El Faro Treatment Intervention

Interventions

Pre - Measures: complete Child Behavior Checklist (CBCL), ADHD module of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI) administered by study team, ADHD Rating Scale (ADHD-RS; parent and teacher ratings), ADHD Functional Impartment Scale (ADHD-FX), Parenting Sense of Competence (PSOC), demographic information, and medical history. \[All rating scales are parent-report unless noted otherwise\] Treatment: Complete an 8-week adapted El Faro treatment intervention with homework tasks. Post-Measures: CBCL, ADHD-RS (parent and teacher ratings), ADHD-FX, and PSOC. We will also acceptability and feasibility via measuring session attendance (rated by the therapist each session), homework completion (rated by the therapist each session), 7 treatment acceptability questions. \[All rating scales are parent-report unless noted otherwise and administered at post-treatment visit unless noted otherwise\].

Treatment Participants

Eligibility Criteria

Age6 Years - 12 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Child is between the ages of 6 to 12 years
  • Child has received a previous diagnosis of ADHD in the community based on caregiver report
  • ADHD Rating Scale (parent rating scale of ADHD symptoms) symptom severity score of 24 or higher
  • Child meets DSM-5 criteria for ADHD (any presentation) based on the MINI
  • Generally healthy (i.e., no major medical problems that will interfere with study participation)
  • Caregiver's willingness to keep any current psychiatric medication regimen for child diagnosed with ADHD constant throughout the study duration
  • Caregiver age 18 years and older
  • Caregiver self-identify as Latinx

You may not qualify if:

  • Caregiver's child has previous diagnosis of Autism, Schizophrenia, or Bipolar Disorder in the community per caregiver report or other psychiatric disorder that is primary to ADHD or may interfere with study involvement.
  • Caregiver unable to attend all El Faro sessions
  • Plan to initiate new ADHD treatment for identified child with ADHD during study participation (previously established ADHD treatments are allowable)
  • Other concerns besides ADHD that would interfere with study participation according to the study team.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Duke University

Durham, North Carolina, 27705, United States

Location

MeSH Terms

Conditions

Attention Deficit Disorder with Hyperactivity

Condition Hierarchy (Ancestors)

Attention Deficit and Disruptive Behavior DisordersNeurodevelopmental DisordersMental Disorders

Study Officials

  • John Mitchell, PhD

    Duke University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: All participants will receive treatment and symptom severity will be measured pre and post-treatment.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 23, 2023

First Posted

July 3, 2023

Study Start

October 10, 2023

Primary Completion

May 30, 2024

Study Completion

May 30, 2024

Last Updated

July 30, 2024

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will not share

There is no IPD for this study.

Locations